
Expanding Access to Sharia Financial Markets, BUMA Offers Its Inaugural Sukuk
PT Bukit Makmur Mandiri Utama (BUMA), a subsidiary of PT Delta Dunia Makmur Tbk (Delta Dunia Group, IDX: DOID), offers its inaugural Sukuk Ijarah, marking another historic milestone in its financial diversification strategy.
The Sukuk, with a maximum amount of Rp2 trillion, is offered in three series with tenors of 370 days, 3 years, and 5 years, providing flexible investment options.
Proceeds will be allocated evenly: 50% for heavy mining equipment and 50% for working capital, driving sustained long-term growth.
BUMA has secured an A+ Syariah rating from Pemeringkat Efek Indonesia (Pefindo) and Fitch Ratings, underscoring its financial strength and operational stability.
JAKARTA, INDONESIA - Media OutReach Newswire - 24 February 2025 - PT Bukit Makmur Mandiri Utama (BUMA), the principal subsidiary of PT Delta Dunia Makmur Tbk (Delta Dunia Group, IDX: DOID), announces the offering of Sukuk Ijarah I BUMA 2025 (the Sukuk), its inaugural Sukuk. With a maximum amount of Rp2 trillion, the Sukuk offering marks another historic milestone in the Group's financial diversification strategy, expanding the Group's investor base into Sharia financial markets.
Sukuk, often referred to as an Islamic bond, is a Sharia-compliant financial instrument similar to conventional bonds but structured to generate returns from underlying asset performance instead of interest, ensuring adherence to Sharia financial principles. The Sukuk Ijarah I BUMA 2025 is offered in three series: Series A with a duration of 370-day tenor, Series B with a 3-year tenor, and Series C with a 5-year tenor, starting from the issuance date. Quarterly Ijarah Fee payments will begin on June 20, 2025, with final bullet payments upon maturity in March 2026, 2028, and 2030. The bookbuilding period takes place from February 24 to March 7, 2025.
Iwan Fuad Salim, Director of Delta Dunia Group, stated, 'The offering of Sukuk Ijarah I BUMA 2025 marks another key milestone in our financing strategy, diversifying our financing sources while enhancing operational capabilities. The strong investor demand for our recently oversubscribed BUMA II 2024 Bond underscores confidence in BUMA's financial strength and disciplined execution. The Sukuk offering further reinforces our credibility and ability to secure diverse funding sources for sustained growth.'
The global Sukuk market continues to expand, driven by rising demand for Sharia-compliant financial instruments and increased government and corporate issuances. Southeast Asia—particularly Indonesia and Malaysia—continues to be a key region, benefiting from a mature Sharia financial ecosystem, strong regulatory frameworks, and established financial institutions. With the global Sukuk market projected to surpass $1 trillion in outstanding assets by 2025, Indonesia is expected to play a major role in sustaining this momentum [1], offering significant opportunities for issuers and investors alike.
'By tapping into the growing Sharia financial market, the Group builds on its diversified financing sources, strengthens its capital structure, broadens its investor base, and reinforces its commitment to financial resilience and operational excellence,' Iwan added.
BUMA successfully secured an A+ Syariah rating from PT Pemeringkat Efek Indonesia (Pefindo) and Fitch Ratings, reflecting the company's financial stability and low default risk profile.
Silfanny Bahar, Director of BUMA, added, 'The proceeds from Sukuk Ijarah I BUMA 2025 will be strategically allocated to support BUMA's long-term growth in Indonesia—50% for capital expenditures, particularly heavy equipment, and 50% for working capital. This initiative strengthens financial resilience while ensuring operational efficiency. BUMA is committed to seizing this momentum to enhance its overall competitive advantage. With a well-defined strategy that expands into mine ownership, commodities, and diversified financing sources, we remain confident in generating long-term value for our stakeholders.'
The Sukuk Ijarah I BUMA 2025 offering is supported by leading arrangers PT BCA Sekuritas, PT BNI Sekuritas, and PT Sucor Sekuritas, with PT Bank Rakyat Indonesia as the trustee.
Hashtag: #DeltaDuniaGroup
The issuer is solely responsible for the content of this announcement.
About PT Delta Dunia Makmur Tbk (Delta Dunia Group):
Established in 1990, PT Delta Dunia Makmur Tbk (Delta Dunia Group) is a prominent holding company operating in Indonesia, Australia, and USA. Our principal subsidiary, PT Bukit Makmur Mandiri Utama (BUMA), is a leading provider of mining services to some of the largest miners in Indonesia and Australia (through BUMA Australia Pty Ltd). In June 2024, through PT Bukit Makmur Internasional (BUMA International), it acquired Atlantic Carbon Group, Inc. (ACG) and became the leading producer of ultra-high-grade anthracite in the USA, further strengthening the Group's global footprint in the mining industry.
In 2023, Delta Dunia Group expanded its portfolio with the addition of two new subsidiaries: PT Bukit Teknologi Digital (BTech), developing AI deep learning technologies to improve operational efficiency, reduce emissions, and minimize Occupational Health and Safety (OHS) operational risks and PT BISA Ruang Nuswantara (BIRU), a social enterprise dedicated to education, vocational schools, and fostering circular economy.
Listed on the Indonesia Stock Exchange (IDX Code: DOID), Delta Dunia Group is headquartered in Jakarta, Indonesia, and is supported by a workforce of over 16,000 employees across Indonesia, Australia, and USA. In June 2024, Delta Dunia Group was recognized among the Top 200 in the inaugural FORTUNE Southeast Asia 500 rankings, a prestigious list that identifies the region's largest companies by revenue.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
5 hours ago
- Business Wire
Abstractive Health Launches Clinical Time Machine, the First AI Game Built on Real Historical Patient Records
NEW YORK--(BUSINESS WIRE)--Abstractive Health has launched Clinical Time Machine, an AI-driven simulation that immerses physicians in diagnostic cases using real historical medical charts. Built on the same HIPAA-compliant platform that powers live summarization of electronic health records (EHRs) in hospital settings, the simulation lets clinicians explore rare, complex cases from hundreds of years ago without patient risk. Abstractive Health's broader goal is to bring clinicians into meaningful, hands-on engagement with AI. Share CEO Vince Hartman calls it 'a Microsoft Flight Simulator for medicine,' enabling diagnostic training on authentic data with no need for EHR integration. 'Three years after ChatGPT, fewer than 1% of physicians have ever seen an AI full medical record summary,' he says. 'We're changing that.' Each case begins with an AI-generated summary distilled from original, centuries-old handwritten documents. Clinicians explore the structured chart, from history of present illness to labs and vitals, and receive simulated updates based on actual clinical observations. 'It's not a quiz. It's about engaging clinical reasoning in a sandbox where doctors can make decisions and learn from them,' Hartman explains. The simulation is built on Abstractive Health's existing summarization and retrieval-augmented generation (RAG) and agentic AI platform. Leveraging advanced OCR and a robust AI summarization pipeline, it can also process handwritten records and turn scribbled notes into readable clinical narratives. The summarization technology is currently being piloted at Weill Cornell Medicine in a research collaboration to assist with writing Emergency Medicine handoff notes. Abstractive Health is also preparing to roll out the experience to Canadian outpatient clinics through a partnership with Canada's WELL Health Technologies that followed an investment and distribution deal inked last year. Abstractive Health's broader goal is to bring clinicians into meaningful, hands-on engagement with AI. 'We're not just saving time - we're helping doctors think better,' Hartman says. 'This is about curiosity, growth, and elevating clinical skill.' Clinical Time Machine is available now through Abstractive's platform for free. About Abstractive Health Abstractive Health retrieves medical records, generates trusted AI summaries, and answers complex clinical questions. Its platform is used by clinicians nationwide and is currently in pilots with Well Health and Weill Cornell Medicine. A top 3 company in the 2024 VA AI Tech Sprint, Abstractive is backed by the NSF and has been featured by Forbes 30 Under 30.


CNBC
15 hours ago
- CNBC
JPMorgan upgrades Newell Brands to overweight thanks to tariff-hedging abilities
Newell Brands ' tariff-hedging advantages gives it a leg up over its peers, according to JPMorgan. The bank upgraded shares of the consumer and commercial goods manufacturer to an overweight rating from neutral. Simultaneously, analyst Andrea Teixeira raised her price target to $7 per share from $6. Newell, which owns brands such as Rubbermaid, Paper Mate, Sharpie, Elmer's, Yankee Candle and Crock-Pot, has stumbled 45% so far this year. However, Teixeira's revised forecast implies an upside of 29% from the stock's Thursday closing price of $5.43. NWL YTD mountain NWL YTD chart One reason for the upgrade comes from a recent meeting with several members of Newell's senior management. "We came away more confident that NWL is finally on the right track to deliver on the turnaround with a more focused portfolio, efficient systems and logistics that should set NWL as a winner in its categories, in particular as the company is a tariff beneficiary with most of its manufacturing in the U.S. vs. abroad for most competitors, including private label," Teixeira wrote. As additional catalysts, the analyst pointed to Newell's increased speed of recent innovation, alongside its distribution gains in key retailers. She added that Newell is also in a good position to hedge tariff risks, and could even gain more market share since most of its peer companies source from abroad. "We think NWL is tariff advantaged with its 15 U.S. plants and two U.S. MCA-compliant plants in Mexico, and is likely to benefit as the company secures more retailer wins in its 19 tariff-advantaged categories, which in turn would aid the top line and in turn gain market share," she wrote. "As it relates to tariff risk for NWL, majority of 15% China sourcing is due to baby gear but this is an industry-wide issue and was exempt under Section 301 during Trump 1.0." Additional tailwinds for Newell Brands include financial deleverage and continuing margin improvement.


Business Wire
17 hours ago
- Business Wire
Ethris Signs Strategic Collaboration with Thermo Fisher Scientific to Provide Access to mRNA Technology Platforms
MUNICH--(BUSINESS WIRE)-- Ethris GmbH, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics and vaccines, today announced a strategic collaboration with Thermo Fisher Scientific, the world leader in serving science, to provide a fully integrated mRNA solution to biopharmaceutical developers. The collaboration brings together Ethris' comprehensive mRNA technology platforms, including its proprietary Stabilized Non-Immunogenic mRNA (SNIM ® RNA), minimal UTR and mRNA manufacturing technologies with Thermo Fisher's industry-leading end-to-end GMP-compliant manufacturing capabilities. Broadening global access to Ethris' comprehensive suite of mRNA technology platforms, the partners will facilitate the ability of biopharmaceutical developers to rapidly advance candidate mRNA medicines from research to clinical proof-of-concept. 'Thermo Fisher Scientific has a long-standing track record of supporting the development of advanced therapies,' said Dr. Carsten Rudolph, CEO of Ethris. 'By combining our clinically validated mRNA platforms with Thermo Fisher's manufacturing expertise, we are creating a powerful offering for biopharma partners. This collaboration addresses the increasing demand for scalable, high-quality mRNA technologies and enables us to serve a broader set of collaborators worldwide.' The collaboration will also support the continued optimization of Ethris' platform technologies, which have already demonstrated positive pharmacodynamic effects, safety and targeted engagement in Phase 1 topline data of its lead candidate, ETH47. Designed for local administration via nasal spray to address the upstream trigger of asthma exacerbations, ETH47 showed dose-dependent, localized production of the encoded protein, interferon lambda at the site of administration, with no systemic bioavailability. The study confirmed that ETH47 activated downstream signaling, demonstrating the expressed protein's functional activity. Given its non-immunogenic nature, SNIM® RNAs can be administered repeatedly, leading to sustained production of therapeutically active proteins within the human body. Eligible for multiple routes of administration, the technology can replace or augment missing or non-functional proteins that cause a disease, introduce new proteins to modulate the course of the disease or its symptoms and be used to develop vaccines. 'Thermo Fisher is committed to supporting the rapid translation of breakthrough therapies into clinical application,' said Ben Castro, Vice President and General Manager, Large Molecule, Drug Substance, Thermo Fisher Scientific. 'By partnering with Ethris, we are expanding our services to include cutting-edge mRNA manufacturing, empowering our customers to bring life-changing treatments to patients faster and more efficiently.' Ethris' SNIM® RNA platform sets new standards for mRNA therapeutics by enabling safe, efficacious and stable drug products as well as scalable manufacturing, expanding the potential of mRNA medicines. About Ethris Ethris, a clinical-stage biotechnology company, has paved a new path from genes to therapeutic proteins, using its proprietary RNA and lipidoid nanoparticle technology platform to discover, design and develop innovative therapies. With more than a decade as an mRNA pioneer, Ethris is a global leader in delivering stabilized mRNAs directly to the respiratory system via optimised formulation and nebulisation technologies. The company is rapidly advancing its mRNA pipeline of immuno-modulation, protein replacement therapies, and differentiated vaccines, with the ultimate goal of improving patients' lives. For more information, visit